

This Page Is Inserted by IFW Operations  
and is not a part of the Official Record

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

# Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism of acquired resistance independent of multidrug resistant protein 4 with a possible role for ATP-binding cassette C11

O. TURRIZIANI\*, J. D. SCHUETZ†<sup>1</sup>, F. FOCHER‡, C. SCAGNOLARI\*, J. SAMPATH†, M. ADACHI†, F. BAMBACIONI\*, E. RIVA§ and G. ANTONELLI\*

\*Department of Experimental Medicine and Pathology, University "La Sapienza", 00185 Rome, Italy, †Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, U.S.A., ‡Institute of Molecular Genetics, CNR, 27100 Pavia, Italy, and §Libera Università "Campus Biomedico", 00155 Rome, Italy

Cellular factors may contribute to the decreased efficacy of chemotherapy in HIV infection. Indeed, prolonged treatment with nucleoside analogues, such as azidothymidine (AZT), 2',3'-dideoxycytidine or 9-(2-phosphonylmethoxyethyl)adenine, induces cellular resistance. We have developed a human T lymphoblastoid cell line (CEM<sub>3TC</sub>) that is selectively resistant to the anti-proliferative effect of 2',3'-dideoxy-3'-thiacytidine (3TC) because the CEM<sub>3TC</sub> cells were equally sensitive to AZT, as well as the antimetabolic agent, vinblastine. The anti-retroviral activity of 3TC against HIV-1 was also severely impaired in the CEM<sub>3TC</sub> cells. Despite similar deoxycytidine kinase activity and unchanged uptake of nucleosides such as AZT and 2'-deoxycytidine, CEM<sub>3TC</sub> had profoundly impaired 3TC accumulation. Further studies

indicated that CEM<sub>3TC</sub> retained much less 3TC. However, despite a small overexpression of multidrug resistance protein (MRP) 4, additional studies with cells specifically engineered to overexpress MRP4 demonstrated there was no impact on either 3TC accumulation or efflux. Finally, an increased expression of the MRP5 homologue, ATP-binding cassette C11 (ABCC11) was observed in the CEM<sub>3TC</sub> cells. We speculate that the decreased 3TC accumulation in the CEM<sub>3TC</sub> might be due to the upregulation of ABCC11.

**Key words:** ABC transporter, HIV, retrovirus, nucleoside analogues.

## INTRODUCTION

Long-term anti-retroviral therapy is the main strategy in clinical treatment of HIV-1 infected patients. It is known that the best results in the efficacy of HIV therapy are obtained when various combinations of drugs are administered. Generally, combination anti-retroviral therapies consist of one or more nucleoside reverse transcriptase inhibitors (NRTIs), protease inhibitors, and/or non-nucleoside reverse transcriptase inhibitors [1–3]. In fact, the combination of two nucleoside-based reverse transcriptase inhibitors and a protease inhibitor, referred to as 'highly active anti-retroviral therapy' (HAART), dramatically suppresses plasma HIV-RNA levels to < 50 copies/ml [4–6]. Despite the efficacy of such therapeutic regimens, long-term treatment with HAART leads to the emergence of drug-resistant HIV strains, and genetic mutations in the reverse transcriptase gene have been isolated in many patients treated with HAART [7–9].

The presence of HIV mutations has been associated with virological failure; however, individuals also display signs of drug resistance in the absence of drug-resistant virus [10,11]. This observation is consistent with the concept that 'cellular' factors contribute to the failure of anti-retroviral therapy [12–15]. Indeed, most anti-HIV agents, specifically dideoxynucleosides, are

phosphorylated by cellular kinases to compounds that inhibit HIV replication. Consequently, decreasing the cellular levels of these compounds could lead to an inability to suppress viral replication and contribute to the failure of anti-retroviral therapy. In this regard, it has been shown that long-term treatment of cell lines with NRTIs [such as 3'-azido-3'-deoxythymidine (AZT) and 2'-3'-dideoxycytidine (ddC)] results in diminished amounts of the phosphorylated forms of NRTIs. In these cases, decreased activity of the cellular kinases leads to antiviral resistance because of an impaired ability to accumulate phosphorylated metabolites [16–18].

Another cellular mechanism has previously been described to explain decreased drug accumulation and resistance to retroviral inhibitors: the increased efflux of phosphorylated drug [19]. Subsequently, we demonstrated that overexpression of a functionally uncharacterized ATP-binding cassette (ABC) drug-transporter [multidrug resistance protein (MRP) 4] was genetically linked to the decreased drug accumulation and resistance to some, but not all NRTIs [20] (for an overview of the ABC-family members and nomenclature see <http://nutrigene.4t.com/humanabc.htm>). The ABC transporters are mostly plasma membrane localized and show ATP-dependent transport of a broad range of compounds. Most MRP substrates are organic

Abbreviations used: ABC, ATP-binding cassette; AZT, 3'-azido-3'-deoxythymidine; CNT, concentrative nucleoside carrier; dCK, deoxycytidine kinase; dCyd, deoxycytidine; ddC, 2'-3'-dideoxycytidine; ENT, equilibrative nucleoside carrier; GFP, green fluorescence protein; HAART, highly active anti-retroviral therapy; [<sup>3</sup>H]Cyd, [<sup>3</sup>H]cytidine; ID<sub>50</sub>, 50% inhibitory dose; MDR, multidrug resistance; [<sup>3</sup>H]AZT, [<sup>3</sup>H]AZT; MRP, multidrug resistant protein; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide; NRTI, nucleoside reverse transcriptase inhibitor; Pgp, P-glycoprotein; PMEA, 9-(2-phosphonylmethoxyethyl)adenine; RT, reverse transcriptase; 3TC, 2',3'-dideoxy-3'-thiacytidine (also called lamivudine); [<sup>3</sup>H]3TC, [<sup>3</sup>H]3TC.

<sup>1</sup> To whom correspondence should be addressed (e-mail [John.schuetz@stjude.org](mailto:John.schuetz@stjude.org)).

anions and they are often conjugated to glutathione, glucuronide or sulphate. Notably, two members of the MRP family (MRP4 and 5) efflux nucleotide analogues such as the nucleotide analogue, 9-(2-phosphorylmethoxyethyl)adenine (PMEA), azidothymidine-monophosphate, and thioguanine-monophosphate [21,22]. Further, the cells that overexpressed MRP4 had decreased antiviral efficacy for 2',3'-dideoxy-3'-thiacytidine (3TC), a finding strongly implicating MRP4 as a contributor to 3TC cellular resistance. In order to evaluate whether the prolonged treatment with 3TC was able to induce cellular resistance by this mechanism, we cultured a T-lymphoblastoid cell line in the presence of increasing concentrations of this nucleoside analogue. Our findings indicate that these cells acquire stable resistance to 3TC by a mechanism whereby 3TC accumulation is substantially decreased. Furthermore, the cells harbor no defect in the enzyme activating 3TC to a nucleotide, nor is there a general impairment in nucleoside uptake. However, despite a small overexpression of MRP4 in these cells, it is clear that another mechanism is responsible because MCF-7 cells engineered to overexpress MRP4 do not show impaired 3TC accumulation or increased 3TC efflux.

## MATERIALS AND METHODS

### Chemicals

The 3TC, kindly provided by Glaxo Wellcome (Stevenage, Herts., U.K.), was dissolved in PBS and kept at  $-20^{\circ}\text{C}$ . AZT, [ $^3\text{H}$ ]AZT ([ $^3\text{H}$ ]AZT, 3 Ci/mmol), ddC and [ $^3\text{H}$ ]cytidine ([ $^3\text{H}$ ]Cyd, 17.4 Ci/mmol) were purchased from Sigma Chemical Co (Milan, Italy). [ $^3\text{H}$ ]3TC ([ $^3\text{H}$ ]3TC, 17.5 Ci/mmol) was purchased from Moravak Biochemicals (Brea, CA, U.S.A.). Commercial reagents and solvents were of analytical grade, unless otherwise stated. [ $^3\text{H}$ ]2'-deoxycytidine ([ $^3\text{H}$ ]dCyd, 18–30 Ci/mmol) was from Amersham (Milan, Italy).

### Selection of 3TC-resistant cell lines

3TC-resistant cells were obtained by exposure of CEM cells, the parental cell line, to increasing concentrations of 3TC. CEM cells were initially propagated in the presence of  $10\text{ }\mu\text{M}$  3TC. Doubling concentrations of 3TC were added to the culture medium and the cells were allowed to grow until they reached a cell density of  $10^6$  cells/ml. After approx. 4 months, a stably resistant 3TC CEM line grew in the presence of  $1\text{ mM}$  3TC, with a doubling time similar to non-drug selected CEM cells. These cells were called CEM<sub>3TC</sub>.

### Assay to determine the anti-growth activity of drugs in CEM and CEM<sub>3TC</sub>

The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assay was used to evaluate the anti-growth activity of drugs in CEM and CEM<sub>3TC</sub> [23]. Briefly, CEM and CEM<sub>3TC</sub> were seeded in 96-well microtitre plates at a concentration of 50 000 cells/well. Different concentrations of drugs were added to triplicate cultures. Four days later,  $20\text{ }\mu\text{l}$  of MTT solution was added to each well and the cultures were incubated at  $37^{\circ}\text{C}$ . The viability of cells was examined spectrophotometrically and the values were used to calculate the 50% toxic concentration ( $\text{TC}_{50}$ ) of the various test compounds.

### Assay of drug sensitivity

CEM and CEM<sub>3TC</sub> cells ( $3 \times 10^5$ ) were incubated with the HIV-PNL43 strain at a multiplicity of infection ('MOI') of 1  $\text{TCID}_{50}$

(50% tissue culture infectious dose)/cell. After 1 h at  $0^{\circ}\text{C}$ , the cultures were washed three times with medium, resuspended in medium containing 3TC (or AZT or ddC) at the appropriate concentrations, and incubated at  $37^{\circ}\text{C}$ . After 5 days the amount of viral antigens produced by infected cells was determined by ELISA (Abbott Laboratories, Abbott Park, IL, U.S.A.). The values for the 50% inhibitory dose ( $\text{ID}_{50}$ ) were calculated from plots of the percentage reduction of viral antigens.

### Determination of intracellular accumulation of 3TC or other nucleosides

CEM and CEM<sub>3TC</sub> cells were treated with [ $^3\text{H}$ ]3TC ( $0.1\text{ }\mu\text{M}$ ;  $2\text{ }\mu\text{Ci/ml}$ ) at different times (as indicated in the Figures) and then rapidly washed with ice-cold buffer and, after lysis, the amount of radioactivity was determined. The intracellular uptake of 3TC was also determined using a range of drug concentrations (from  $0.02\text{ }\mu\text{M}$  to  $0.2\text{ }\mu\text{M}$ ). To study the intracellular accumulation of AZT and dCyd, CEM and CEM<sub>3TC</sub> cells were exposed to [ $^3\text{H}$ ]AZT ( $0.6\text{ }\mu\text{M}$ ;  $2\text{ }\mu\text{Ci/ml}$ ) and [ $^3\text{H}$ ]dCyd ( $0.1\text{ }\mu\text{M}$ ;  $2\text{ }\mu\text{Ci/ml}$ ). At the indicated time, cells were washed, lysed and the radioactivity was determined.

### 3TC retention

CEM and CEM<sub>3TC</sub> were preincubated with [ $^3\text{H}$ ]3TC ( $2\text{ }\mu\text{Ci/ml}$ ) for 2 h, washed with ice-cold PBS by centrifugation, resuspended in drug-free medium, and maintained at  $37^{\circ}\text{C}$ . After 1 h, the intracellular radioactivity and radiolabelled drug released into the medium was assessed by scintillation counting.

### Reverse transcription (RT) and PCR

RNA from  $5 \times 10^6$  CEM or CEM<sub>3TC</sub> was isolated using Trizol reagents (Gibco BRL, NY, U.S.A.). The RT-PCR analysis of the RNA sample was performed as follows. RNA ( $10\text{ }\mu\text{g}$ ) was incubated with  $2\text{ }\mu\text{l}$  of random primers ( $150\text{ }\mu\text{g/ml}$ ) at  $72^{\circ}\text{C}$  for 10 min, then combined with a mixture containing  $4\text{ }\mu\text{l}$  of 5% reaction buffer [250 mM Tris (pH 8.3), 375 mM KCl, 15 mM  $\text{MgCl}_2$ ; Roche Molecular Biochemicals, Milan, Italy], 25 units of human placental ribonuclease inhibitor,  $1\text{ }\mu\text{l}$  of 10 mM dNTP (Roche Molecular Biochemicals), 8 units of Moloney murine leukaemia virus RT (Roche Molecular Biochemicals). After 90 min at  $42^{\circ}\text{C}$ ,  $5\text{ }\mu\text{l}$  of cDNA was subjected to the PCR-mediated amplification for P-glycoprotein (Pgp) according to conditions described previously [24].

### Cell extracts

CEM and CEM<sub>3TC</sub> cell pellets, prepared as described above, were resuspended in 5 vols of 20 mM Bis-Tris, pH 6.5, containing 1 mM dithiothreitol (DTT) and 0.5 mM PMSF, and sonicated for 5 s on ice at 50 W. Sonication was repeated five times at intervals of 10 s. Cell extracts were centrifuged at  $4^{\circ}\text{C}$  at 5000 g in a benchtop centrifuge for 15 min. Supernatants were collected and assayed for protein concentration using the spectrophotometric-based Bio-Rad Protein Assay.

### 2'-Deoxycytidine kinase assay

Deoxycytidine kinase (dCK) activity present in cell extracts was assayed with a radiochemical method which measures the formation of [ $^3\text{H}$ ]dCMP from [ $^3\text{H}$ ]dCyd. The cell extracts were incubated at  $37^{\circ}\text{C}$  in  $25\text{ }\mu\text{l}$  of a mixture containing 30 mM Hepes- $\text{K}^+$  (pH 7.5), 5 mM  $\text{MgCl}_2$ , 5 mM ATP, 0.5 mM DTT and  $2.4\text{ }\mu\text{M}$  [ $^3\text{H}$ ]dCyd ( $2200\text{ c.p.m./pmole}$ ) or [ $^3\text{H}$ ]3TC

(1500 c.p.m./pmole). The reaction, after 20 min incubation, was terminated by spotting 20  $\mu$ l of the incubation mixture onto a 25 mm DEAE paper disk (DE-81 paper; Whatman Biosystems Ltd., Maidstone, Kent, U.K.). The disks were washed three times in an excess of 1 mM ammonium formate, pH 3.6, in order to remove unconverted nucleoside, followed by a final wash in ethanol. The filters were dried and radioactive dCMP was estimated by scintillation counting in 1 ml of Betamax scintillating fluid (ICN Pharmaceuticals, Milan, Italy). One unit is defined as the amount of enzyme catalysing the formation of 1 nmol of dCMP in 1 h at 37 °C.

#### Immunoblot analysis

Crude membranes were prepared from cells as described previously [20]. Proteins were estimated using the Bio-Rad Protein Assay (Bio-Rad, Milan, Italy) and BSA was used as the standard. The crude membrane proteins (200  $\mu$ g) were resuspended in standard Laemmli sample preparation buffer and loaded onto a 7.5% denaturing polyacrylamide gel and transferred to nitrocellulose filters. The filters were blocked in 1  $\times$  PBS containing 0.1% Tween 20 and 10% non-fat dry milk, immunoreacted with polyclonal rabbit anti-(MRP4) IgG followed by peroxidase conjugated anti-(rabbit IgG), and then developed with the Amersham ECL<sup>®</sup> detection system (Amersham, Arlington Heights, IL, U.S.A.). The immunoblots were stripped with glycine and reprobed with a monoclonal antibody to MRP1 (mPr1; Signet Laboratories, MA, U.S.A.).

#### Pgp detection

Pgp was also detected by FACS analysis. CEM, CEM<sub>3TC</sub> and CEMVBL100 (a T-cell line expressing a high level of Pgp) cells were incubated with a Pgp-specific monoclonal antibody that recognizes an external epitope of Pgp (mMRK16, Alexis Italia, Florence, Italy). After incubation (30 min at 18–25 °C) the cells were washed with PBS and incubated with FITC-labelled goat anti-mouse immunoglobulin (Bioline Diagnostics, Turin, Italy) for an additional 30 min. After washing with PBS, the cells were resuspended in PBS and analysed by flow cytometry. This was performed using a FACScan (DAKO-Galaxy, Milan, Italy) flow cytometer. Forward and side light scatter were collected in linear mode and served to exclude unwanted events (i.e. debris, dead cells and aggregates). The fluorescence signal was collected in the log mode.

#### Generation of MRP4 stable cell lines

The human MRP4 cDNA was cloned into the MSCV-IRES-GFP [25] vector (kindly provided by Dr Robert Hawley, Holland Laboratory, American Red Cross, Rockville, MD, U.S.A.) using the *EcoRI* site. 293T cells were cotransfected with 10  $\mu$ g each of MSCV-MRP4-IRES-GFP, the helper plasmid pSRa-G, and pEQPAM3-e (kindly supplied by P. Kelly and E. F. Vanin, Department of Hematology/Oncology St Jude Children's Research Hospital, Memphis, TN, U.S.A.) by standard calcium phosphate precipitation [26]. The supernatant was collected 48 h after transfection, filtered, titred and frozen at –80 °C. To confirm transfection, the 293T cells were analysed for green fluorescence protein (GFP) expression. Subsequently, the cells were transduced with MRP4. Briefly, the cells were plated at  $5 \times 10^4$  cells/60 mm tissue culture dish and then the medium was replaced by the retroviral supernatant supplemented with 6  $\mu$ g/ml polybrene and placed overnight in an incubator at 37 °C in a 5% CO<sub>2</sub> humidified atmosphere. The transduction was repeated again twice for a total of three times. The transduced cells were

expanded and the GFP-positive cells were selected after FACS [26]. Subsequently, a total lysate was prepared and loaded on a denaturing polyacrylamide gel for MRP4 and MRP1 detection by immunoblot [20].

#### Semi-quantitative RT-PCR analysis of MRP5 and ABCC11

RNA was isolated from CEM and CEM<sub>3TC</sub> cells using Trizol. First-strand cDNA was made from 2.5  $\mu$ g of RNA using the cDNA synthesis kit for PCR (Boehringer Mannheim, Indianapolis, IN, U.S.A.) in a final volume of 20  $\mu$ l. MRP5 and ABCC11 (also called MRP8) were amplified with 125 ng of cDNA in a final volume of 50  $\mu$ l containing 200  $\mu$ M each of dATP, dCTP, dGTP, and dTTP, and 300 nM each of forward and reverse primers using the Expand High Fidelity PCR System (Boehringer Mannheim). Samples were denatured for 5 min at 94 °C, followed by cycles of 94 °C for 30 s, 60 °C for 30 s, 68 °C for 2 min, and a final incubation at 68 °C for 2 min. The number of cycles for MRP5 was 26 and the number of cycles for ABCC11 was 30. Primers were as follows: MRP5, forward primer, 5'-TCCTGCCTTCTGCTCCTGGTGT-3' and reverse primer, 5'-CTGTGCGACGACTGCGGTGAG-3'; ABCC11 forward primer, 5'-AGAATGGCTGTGAAGGCTCAGC-3' and reverse primer, 5'-GTTCTCTCCAGCTCCAGTGC-3'. The predicted sizes for the MRP5 and ABCC11 products were 390 bp and 550 bp respectively. Aliquots (10  $\mu$ l) of the PCR reactions were loaded onto a 1% agarose gel containing ethidium bromide.

## RESULTS

#### Selection of 3TC-resistant CEM cells

Cellular factors, such as altered drug activation and/or decreased accumulation may cause failure of anti-retroviral drugs [13–15]. To determine if these cellular factors account for the variable response to the anti-retroviral drug 3TC, we cultured the CEM T-cell line in increasing concentrations of 3TC. After approx. 4 months of culture in the presence of 1 mM 3TC, CEM cells were obtained that were refractory to the growth inhibitory properties of 3TC. These cells are referred to as CEM<sub>3TC</sub> and their resistance to 3TC was stable for 4 months in the absence of 3TC. Furthermore, the resistance to the cytotoxic effects of 3TC was selective because CEM<sub>3TC</sub> were equally sensitive to AZT and vinblastine (Table 1).

#### CEM<sub>3TC</sub> are impaired for antiviral efficacy

To evaluate whether the CEM<sub>3TC</sub> cells had an impaired ability to inhibit HIV replication, CEM and CEM<sub>3TC</sub> cells were infected with HIV (see Materials and methods section) and then treated


**Table 1** Sensitivity of CEM and CEM<sub>3TC</sub> to antiviral and antigrowth activities of 3TC, AZT, ddC and vinblastine

TC<sub>50</sub> is the concentration producing 50% cytotoxicity and ID<sub>50</sub> is the dose producing 50% inhibition of HIV replication.

Cells	TC <sub>50</sub>			ID <sub>50</sub>		
	3TC (mM)	AZT (mM)	VBL (ng/ml)	3TC (nM)	AZT (nM)	ddC (nM)
CEM	4.00 $\pm$ 2	0.30 $\pm$ 0.10	0.08 $\pm$ 0.06	6 $\pm$ 3	7 $\pm$ 4	8 $\pm$ 3
CEM <sub>3TC</sub>	> 10†	0.40 $\pm$ 0.15	0.10 $\pm$ 0.09	60 $\pm$ 10*	9 $\pm$ 5	10 $\pm$ 4

† Owing to 3TC insolubility, concentrations greater than 10 mM were not evaluated.

\* CEM versus CEM<sub>3TC</sub>, *P* < 0.05.



**Figure 1** Antiviral activity is reduced in 3TC resistant cells

Antiviral activity of 3TC in CEM (diamonds) and CEM<sub>3TC</sub> (squares). Cells were infected with HIV-PNL43 and cultured in the presence of different concentrations of 3TC. After 5 days the amount of viral antigen produced by infected cells was measured as described in the Material and methods section. Each point represents the mean and the bars  $\pm$  one standard deviation from the mean.


with various concentrations of 3TC (Figure 1). The viral yield was determined 5 days later by measuring the viral antigen released into the culture supernatant. We found that CEM<sub>3TC</sub> were markedly resistant to the antiviral activity of 3TC, with the 3TC ID<sub>50</sub> value for HIV-1 being approx. 10-fold higher in CEM<sub>3TC</sub> (ID<sub>50</sub> = 60 nM) compared with the CEM cell line (ID<sub>50</sub> = 6.0 nM) (Figure 1). Again, the resistance to the antiviral activity of 3TC was selective because CEM<sub>3TC</sub> were equally sensitive to the antiviral activity of ddC and AZT (Table 1).

#### Deoxycytidine kinase activity is not decreased in CEM<sub>3TC</sub>

After cellular uptake by nucleoside uptake carriers, 3TC is phosphorylated by deoxycytidine kinase [27]. Deoxycytidine kinase effectively phosphorylates both enantiomers of dCyd [28] and dCyd analogues, such as 3TC [29]. Therefore, we evaluated the enzymic activity of dCK in CEM and CEM<sub>3TC</sub> cells using both 3TC and dCyd as the substrate. The results indicated that the enzymic activity of dCK from CEM<sub>3TC</sub> was not decreased compared with the parental CEM cells. In fact, using 3TC as substrate, the dCK activity was  $0.12 \pm 0.01$  units/mg of protein in CEM and  $0.16 \pm 0.02$  units/mg in CEM<sub>3TC</sub>. Similarly, when dCyd was used as substrate the dCK activity was  $0.8 \pm 0.08$  units/mg in CEM and  $1.24 \pm 0.12$  units/mg in CEM<sub>3TC</sub>. These results indicate, using either dCyd or 3TC, that the 3TC-resistance of CEM<sub>3TC</sub> cannot simply be ascribed to a reduction in dCK activity.

#### Decreased 3TC accumulation in CEM<sub>3TC</sub> without a general decrease in nucleoside uptake


Resistance to 3TC could be due to the reduced intracellular accumulation of drug, secondary to either transport changes or alterations in enzymic activation. Uptake of radiolabelled 3TC was used to assess variations in 3TC transport. Figure 2(A) shows there was no significant difference between the two cell lines in their initial uptake of 3TC (< 50 min). However, when the cells were incubated for longer intervals (> 1 h) dramatic differences in accumulation emerged. The CEM cells continued to accumulate radiolabelled 3TC, whereas at 8 h, the CEM<sub>3TC</sub> achieved a steady-state level of drug that was as much as 3-fold



**Figure 2** 3TC Accumulation is impaired in 3TC resistant cells

(A) Intracellular uptake of [<sup>3</sup>H]3TC in CEM (open bars) and CEM<sub>3TC</sub> (closed bars). Cell cultures were incubated with 0.1 μM [<sup>3</sup>H]3TC, and at the indicated times cells were extensively washed with ice-cold PBS, lysed and the radioactivity determined by scintillation counting. The results are the mean ( $\pm$  SD) from three independent experiments (\**P* < 0.05). (B) Long-term 3TC accumulation. Either CEM (open bars) or CEM<sub>3TC</sub> (closed bars) were incubated with 0.1 μM [<sup>3</sup>H]3TC for the indicated intervals (\**P* < 0.05). (C) Uptake of different concentrations of [<sup>3</sup>H]3TC. After 8 h, intracellular radioactivity was evaluated by scintillation counting. The points represent the mean of two independent experiments performed in triplicate, with the error bars indicating  $\pm$  one standard deviation (\**P* < 0.05).

lower than the maximum attained in the CEM cells. It is interesting to note that despite the continued presence of extracellular drug, the 3TC accumulation decreased in the CEM cells after 72 h of 3TC incubation. This suggests that the transporter effluxing 3TC is induced, a phenomenon previously reported for AZT [30] (Figure 2B). Finally, the CEM<sub>3TC</sub> cells accumulated much less drug than the CEM cells at multiple concentrations of 3TC (Figure 2C). It is notable that the 5-fold lower 3TC accumulation roughly corresponds with the greater 3TC concentration required to inhibit HIV replication (Figure 1 and Table 1) and supports the idea that impaired 3TC accumulation is responsible for the enhanced survival of these cells in 3TC, as well as the requirement for more 3TC to inhibit HIV replication.



**Figure 3** 3TC resistant cells have a selective defect in 3TC accumulation

Intracellular accumulation of 3TC, AZT and dCyd in CEM (open bars) and CEM<sub>3TC</sub> (solid bars). Cells were incubated with (A) 0.1  $\mu$ M [<sup>3</sup>H]3TC, (B) 0.6  $\mu$ M [<sup>3</sup>H]AZT or (C) 0.1  $\mu$ M [<sup>3</sup>H]dCyd. At the indicated times, cells were washed with ice-cold PBS, lysed and the radioactivity determined by scintillation counting. The results are the average of two independent experiments done in triplicate.

**Table 2** 3TC drug accumulation and retention in 3TC resistant cells

The values are the means of two independent experiments, each done in duplicate. For both intracellular radioactivity and radioactivity released into the supernatant, values were significantly different,  $P < 0.05$  in each case.

Cells	Percentage of total [ <sup>3</sup> H]3TC	
	Intracellular	Supernatant
CEM	82.4 $\pm$ 1.8	17.6 $\pm$ 1.8
CEM <sub>3TC</sub>	65.7 $\pm$ 0.8	34.3 $\pm$ 0.8

To determine if the impaired accumulation of 3TC was specific for 3TC, and to rule out a general defect in nucleoside uptake carriers, accumulation of [<sup>3</sup>H]3TC, [<sup>3</sup>H]AZT and [<sup>3</sup>H]dCyd was determined (Figure 3). It is known that AZT is a substrate for both the concentrative nucleoside carrier (CNT) and equilibrative nucleoside carrier (ENT2) [31], while deoxycytidine is a known substrate for CNT [32]. The intracellular radioactivity was then measured as described in the Material and methods section. The studies reveal that CEM<sub>3TC</sub> cells are not impaired for the accumulation [<sup>3</sup>H]AZT and [<sup>3</sup>H]dCyd, which indicates that the nucleoside-uptake carriers transporting these nucleosides are not impaired in the CEM<sub>3TC</sub> cells.

#### CEM<sub>3TC</sub> have decreased retention of 3TC, with no change in Pgp and a small increase in MRP4 expression

To explore whether the defect in cellular 3TC accumulation could be associated with a decreased capability of the resistant

cell line to retain 3TC, we evaluated 3TC retention. The cells were pre-loaded with [<sup>3</sup>H]3TC followed by resuspension in drug-free media. Subsequently, the amount of radioactivity in the cells and media was determined. The results, shown in Table 2, indicate that the CEM<sub>3TC</sub> cells retained much less intracellular radioactivity than the CEM cells. Furthermore, a correspondingly higher percentage of radioactivity was released into the medium from CEM<sub>3TC</sub> compared with CEM cells. This indicates that CEM<sub>3TC</sub> have a decreased ability to retain 3TC, and this correlates with the selective impaired accumulation of 3TC (Figure 2).

Next, we evaluated whether the decreased 3TC accumulation could be due to an increased expression of Pgp using FACS analysis with an antibody that detects a surface Pgp epitope (see Materials and methods section). We found that both CEM and CEM<sub>3TC</sub> have undetectable Pgp, unlike the positive control, CEMVBL<sub>100</sub>, that expresses high amounts of Pgp (results not shown). Furthermore, we demonstrated that neither the CEM nor CEM<sub>3TC</sub> cells had detectable levels of MDR1 transcript when used amplified to the same extent as the MDR1-positive cell, CEMVBL<sub>100</sub>.

#### Expression of MRP4 in CEM<sub>3TC</sub> and transport of 3TC in cells ectopically expressing MRP4

Recent studies indicated that the ABC transporter, MRP4, plays a role in the cellular resistance to anti-retroviral nucleoside drugs, including 3TC [20]. To evaluate MRP4 expression, we performed immunoblot analysis on crude membranes from the CEM<sub>3TC</sub> cells (Figure 4). We found that the level of immunoreactive MRP4 increased approximately 2-fold in the CEM<sub>3TC</sub> cells. In contrast, MRP1 was not different in the two cell lines. It is interesting to note that MRP4, which is only a 1325-amino-acid-residue protein, runs at an estimated size of 220 kDa, whereas MRP1, a 1531-amino-acid-residue protein, runs at an estimated size of 190 kDa. This is probably due to the fact that MRP4 is extensively glycosylated with at least seven predicted N-linked asparagine glycosylation sites [25].

To determine whether MRP4 played a role in transport of 3TC, we developed cell lines that ectopically overexpressed MRP4 (Figure 4B). We confirmed the phenotype of these cells by evaluating the uptake of PMEA, a known MRP4 substrate [20] (Figure 4C). These cells were then assessed for the uptake of 3TC (Figure 4D). We evaluated 3TC uptake after a 24 h incubation in concentrations of 3TC from 0.5 to 10  $\mu$ M. The total accumulation of 3TC radioactivity was the same in the MRP4 cells as in the vector-only transfected cells (Figure 4D). Since longer incubations (48 h) produced slightly lower 3TC accumulation, we assessed whether efflux was faster in the MRP4 cells. The cells were loaded with 3TC, resuspended in drug-free media, and then assessed for both 3TC intracellular-associated radioactivity and the radioactivity released into the media (Figure 4E). For both cells lines, the time to decrease the intracellular radioactivity to one-half the initial level was approx. 20 min and, notably, a corresponding efflux of radioactivity into the media occurred. These studies directly demonstrate in MCF-7 cells overexpressing MRP4 that 3TC efflux is not enhanced by MRP4 overexpression.

#### Expression of MRP4, MRP5 and ABCC11 in CEM<sub>3TC</sub>

The efflux of nucleotide analogues in mammalian cells has been confirmed for MRP4 and MRP5 [21]. Although we have demonstrated that cells specifically overexpressing MRP4 do not have




Figure 4 Analysis of MRP1 and MRP4 in CEM<sub>3TC</sub> and the impact of MRP4 upon 3TC transport

(A) Lysates of CEM and CEM<sub>3TC</sub> cells were analysed on an immunoblot with antiserum against MRP4, and then with antiserum against MRP1. (B) Immunoblot analysis of MRP4 expression in cells engineered to overexpress MRP4. (C) Functional analysis of MRP4 using PMEA accumulation, as described in the Materials and methods section. (D) MCF-7 cells ectopically expressing MRP4 (●) or the control vector (○) were incubated with [ $^3$ H]3TC (0.5–10  $\mu$ M). After 24 h, the accumulation of 3TC radioactivity was determined. (E) 3TC efflux in cells ectopically expressing MRP4. Control vector (○) and MRP4 expressing cells (●) were loaded with [ $^3$ H]3TC followed by resuspension in drug-free media. Both intracellular-associated 3TC radioactivity (Cell Associated) and 3TC radioactivity released into the media (Supernatant) were assessed.




Figure 5 Analysis of MRP5 and ABCC11 (MRP8) expression in CEM<sub>3TC</sub> cells

Total RNA was isolated from both CEM and CEM<sub>3TC</sub> cells, followed by RT-PCR. The lower band in MRP8 (ABCC11) was sequenced and found to be a non-specific band. The primers and conditions are described in the Materials and methods section.

decreased accumulation or increased efflux of 3TC, it remains possible that another ABC transporter effluxes 3TC metabolites. Our recent investigations and others studies [33,34] indicate that MRP5 has two closely related homologues on chromosome 16. We evaluated the expression of ABCC11 mRNA levels in CEM and CEM<sub>3TC</sub> cells by RT-PCR (ABCC12 was not detected). In addition, we assessed the level of MRP5 mRNA (Figure 5). We found that the level of MRP5 was unchanged in the CEM<sub>3TC</sub> cells. In contrast, semi-quantitative RT-PCR revealed that ABCC11 was increased 6-fold. The magnitude of this increase in ABCC11 mRNA is comparable with the impairment in 3TC antiviral efficacy in these cells. The lack of a direct correspondence may be due to the possibility that the protein is expressed at a much higher level than the mRNA; however, at this time, it is impossible to determine whether ABCC11 protein levels are increased due to the unavailability of a specific antibody.

## DISCUSSION

Recent findings have recognized that anti-retroviral drug treatment causes a phenotype described as cellular resistance [12–15]. This phenomenon is consistent with the knowledge that different cell lines require a broad range in the concentration of anti-retroviral drug to inhibit HIV replication [35]. Two main mechanisms contribute to cellular resistance: altered metabolism of nucleoside analogues due to impaired nucleoside phosphoryl-

ation and increased efflux of the compounds by membrane transport mechanisms [20,21].

Our results demonstrate that prolonged treatment with 3TC selects for cells with an acquired, stable resistance to 3TC. Compared with the CEM cells, CEM<sub>3TC</sub> required about 10-fold more 3TC to inhibit HIV. Moreover, these cells showed increased resistance to the cytotoxic effects of 3TC. However, the CEM<sub>3TC</sub> were as sensitive to AZT, ddC and vinblastine as the CEM cells, demonstrating that this resistance is specific for 3TC. Notably, 3TC resistance was not due to decreased dCK activity, the principal enzyme required for activation of 3TC [27]. Furthermore, uptake of the natural nucleosides dCyd and azidothymidine was unaltered in CEM<sub>3TC</sub>. Thus, these findings rule out the possibility of a general defect in nucleoside uptake because such alterations would have undoubtedly have impacted upon AZT and dCyd accumulation, considering that AZT is transported by both ENT2 and CNT, and that dCyd is transported by CNT [32,36]. In contrast, 3TC accumulation was substantially reduced in CEM<sub>3TC</sub> cells and was associated with decreased intracellular retention. Consequently, we postulated that an efflux transporter was responsible for preventing 3TC accumulation in the resistant cells. In fact, drug efflux pumps are an important part of the cellular defence against cytotoxic compounds. Specifically, cells overexpressing drug-transporting proteins become resistant to a wide range of drugs with different structures and/or cellular targets. This phenomenon is known as multidrug resistance (MDR). The most well characterized of these drug transporters is Pgp [37]. The overexpression of Pgp has been described for many cancer cells with acquired resistance to chemotherapeutics [38]. Several studies have reported that Pgp-expressing cells are also resistant to the anti-growth and antiviral activity of some NRTIs [39–41]. On the basis of these findings, we evaluated Pgp expression in CEM<sub>3TC</sub>. However, as anticipated, based upon 3TC structure, the CEM<sub>3TC</sub> cells had no detectable Pgp overexpression.

Recently, it has been reported that one member of the MRP family, MRP4, is overexpressed in cells that acquire resistance to the cytotoxic effects of the modified nucleotide analogue, PMEA [20]. Notably, overexpression of MRP4 impairs the antiviral efficacy of PMEA and other nucleoside analogues, such as 3TC and AZT. In our 3TC resistant cells, we found a small increase in MRP4 (< 2-fold), suggesting that 3TC metabolites could be MRP4 substrates. However, an analysis of MCF-7 cells ectopically expressing MRP4 showed that MRP4 does not affect either the accumulation or the efflux of 3TC. This result contrasts with the previously reported findings; however, it should be noted that only PMEA and AZT-monophosphate were effluxed to a greater extent in the MRP4 overexpressing cells, and it was not directly demonstrated that 3TC metabolites were more readily effluxed in those cells [20]. Thus, based on the current studies, it seems unlikely that MRP4-mediated efflux is directly involved in cellular 3TC resistance and that the impaired 3TC accumulation and decreased retention is due to an additional 3TC transporter in the CEM<sub>3TC</sub> cells. Since MRP5 has been demonstrated to transport similar substrates as MRP4 [21], we evaluated its mRNA expression, but found no difference in MRP5 expression in the CEM<sub>3TC</sub> cells. However, recent studies [33] have determined that MRP4 and MRP5 homologues are found on chromosome 16q12. These homologous genes also lack an N-terminal domain that is found in the prototypical ABCC1 (i.e. MRP1). In the CEM<sub>3TC</sub> cells, we found increases in ABCC11 mRNA expression (6-fold). However, in the absence of an antibody we are unable, at this time, to confirm if ABC11 protein is overexpressed. Nevertheless, it is possible that this transporter contributes to the efflux-mediated resistance to 3TC.

In conclusion, our results are most consistent with the concept that 3TC resistance is mediated by an inability to adequately accumulate 3TC. This is not due to impaired 3TC phosphorylation or initial uptake. It is possible that increased ABCC11 expression decreases 3TC accumulation and increases cellular 3TC resistance. However, at the present time, we cannot directly confirm this possibility. The current studies support the idea that 3TC resistance may be due to ABC11 overexpression. However, we can not exclude the likelihood that a combination of increased MRP4 and ABCC11 underlie the 3TC resistance and impaired accumulation in these cells. This might be analogous to the overexpression and potential role of MRP1, MRP2 and ABCG2 in cells in resistance to the camptothecin class of cancer chemotherapeutic drugs [42]. Future studies will address the possibility of such interactions among ABCC11 and MRP4.

Supported by a grant from Ministero della Sanità-ISS (AIDS Project, grant no. 30C.5 to G.A.) and by a grant from National Institutes of Health GM 60904 (J.S.), P30 CA21765, and American Lebanese Syrian Associated Charities, ALSAC (J.S.).

## REFERENCES

- Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Richman, D. D., Valentine, F. T., Jonas, L., Meibohm, A. et al. (1997) Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. *N. Engl. J. Med.* **337**, 734–739.
- Gulick, R. M., Mellors, J. W., Havlir, D., Eron, J. J., Gonzalez, C., McMahon, D., Jonas, L., Meibohm, A., Holder, D., Schleif, W. A. et al. (1998) Simultaneous vs sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100-week follow-up. *J. Am. Med. Assoc. JAMA* **280**, 35–41.
- Cameron, D. W., Japour, A. J., Xu, Y., Hsu, A., Mellors, J., Farthing, C., Cohen, C., Poretz, D., Markowitz, M., Follansbee, S. et al. (1999) Ritonavir and saquinavir combination therapy for the treatment of HIV infection. *AIDS (London)* **13**, 213–224.
- Wong, J. K., Hezareh, M., Gunthard, H. F., Havlir, D. V., Ignacio, C. C., Spina, C. A. and Richman, D. D. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. *Science* **278**, 1291–1295.
- Finzi, D., Hermankova, M., Pierson, T., Carruth, L. M., Buck, C., Chaisson, R. E., Quinn, T. C., Chadwick, K., Margolick, J., Brookmeyer, R. et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. *Science* **278**, 1295–1300.
- Zhang, L., Ramratnam, B., Tenner-Racz, K., He, Y., Vesanen, M., Lewin, S., Talal, A., Racz, P., Perelson, A. S., Korber, B. T. et al. (1999) Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. *N. Engl. J. Med.* **340**, 1605–1613.
- Gunthard, H. F., Wong, J. K., Ignacio, C. C., Guatelli, J. C., Riggs, N. L., Havlir, D. V. and Richman, D. D. (1998) Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. *J. Virol.* **72**, 2422–2428.
- O'Brien, W. A. (2000) Resistance against reverse transcriptase inhibitors. *Clin. Infect. Dis.* **30**, S185–S192.
- Martinez-Picado, J., De Pasquale, M. P., Karlsson, N., Hanna, G. J., Wong, J., Finzi, D., Rosenberg, E., Gunthard, H. F., Sutton, L., Savara, A. et al. (2000) Antiretroviral resistance during successful therapy of HIV type 1 infection. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 10948–10953.
- Di Gregorio, P., Iacobelli, S., Perrin, L. and Telenti, A. (1998) HIV treatment failure: testing for HIV resistance in clinical practice. *Science* **280**, 1871–1872.
- Durant, J., Clevenbergh, P., Hatton, P., Delgiudice, P., Porsin, S., Simonet, P., Montagne, N., Boucher, C. A., Schapiro, J. M. and Dellamonica, P. (1999) Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. *Lancet* **353**, 2195–2199.
- Dianzani, F., Antonelli, G., Turriziani, O., Riva, E., Simeoni, E., Signoretti, C., Strosselli, S. and Cianfriglia, M. (1994) Zidovudine induces the expression of cellular resistance affecting its antiviral activities. *AIDS Res. Hum. Retroviruses* **10**, 1471–1478.
- Groschel, B., Cinatl, J. and Cinatl, J. Jr (1997) Viral and cellular factors for resistance against antiretroviral agents. *Intervirology* **14**, 400–407.
- Fridland, A., Connelly, M. C. and Robbins, B. L. (2000) Cellular factors for resistance against antiretroviral agents. *Antiviral Ther.* **5**, 181–185.
- Turriziani, O., Antonelli, G. and Dianzani, F. (2000) Cellular factors involved in the induction of resistance of HIV to antiretroviral agents. *Int. J. Antimicrob. Agents* **16**, 353–356.



- 16 Avramis, V. I., Kwock, R., Solorzano, M. M. and Gomperts, E. (1993) Evidence of *in vitro* development of drug resistance to azidothymidine in T-lymphotropic leukemia cell line (Jurkat E6-1/AZT-100) and in pediatric patients with HIV infection. *J. Acquired Immune Defic. Syndr.* **6**, 1287–1296.
- 17 Magnani, M., Brandi, G., Casabianca, A., Fraternali, A., Schiavano, F., Rossi, L. and Chiarantini, L. (1995) 2',2'-Dideoxycytidine metabolism in a new drug-resistant cell line. *Biochem. J.* **312**, 115–123.
- 18 Antonelli, G., Turriziani, O., Verri, A., Narciso, P., Ferri, F., D'Offizi, G. and Dianzani, F. (1996) Long-term exposure to zidovudine affects *in vitro* and *in vivo* the efficiency of phosphorylation of thymidine kinase. *AIDS Res. Hum. Retroviruses* **12**, 223–228.
- 19 Robbins, B. L., Connelly, M. C., Marshall, D. R., Srinivas, R. V. and Fridland, A. (1995) A human T lymphoid cells variant resistant to the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxyethyl)adenine shows a unique combination of a phosphorylation defect and increased efflux of the agent. *Mol. Pharmacol.* **47**, 391–397.
- 20 Schuetz, J. D., Connelly, M. C., Sun, D., Paibir, S. G., Flynn, P. M., Srinivas, R. V., Kumar, A. and Fridland, A. (1999) MRP4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. *Nat. Med. (N.Y.)* **5**, 1048–1051.
- 21 Wijnholds, J., Mol, C. A., van Deemter, L., de Haas, M., Scheffer, G. L., Baas, F., Beijnen, J. H., Schepers, R. J., Hatse, S., De Clercq, E., Balzarini, J. and Borst, P. (2000) Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs. *Proc. Natl. Acad. Sci. U.S.A.* **97**, 7476–7481.
- 22 Borst, P., Evers, R., Kool, M. and Wijnholds, J. (2000) A family of drug transporters: the multidrug resistance-associated proteins. *J. Nat. Cancer Inst.* **92**, 1295–1302.
- 23 Denizot, F. and Lang, R. (1986) Rapid colorimetric assay for cell growth and survival. *J. Immunol. Methods* **89**, 271–277.
- 24 El-Osta, A., Kantharidis, P. and Zalcberg, J. (1999) Absolute quantitation of MDR1 transcripts using heterologous DNA standards-validation of the competitive RT-PCR (CRT-PCR) approach. *BioTechniques* **26**, 1114–1124.
- 25 Adachi, M., Sampath, J., Lan, L. B., Sun, D., Hargrove, P., Flatley, R. M., Tatum, A., Ziegelmeier, M. Z., Wezeman, M., Matherly, L. H. et al. (2002) Expression of MRP4 confers resistance to ganciclovir and compromises bystander killing. *J. Biol. Chem.*, in the press.
- 26 Lecureur, V., Sun, D., Hargrove, P., Schuetz, E. G., Kim, R. B., Lan, L. B. and Schuetz, J. D. (2000) Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein. *Mol. Pharmacol.* **57**, 24–35.
- 27 Chang, C. N., Skalski, V., Zhou, J. H. and Cheng, Y. (1992) Biochemical Pharmacology of (+) and (–)-2',3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents. *J. Biol. Chem.* **267**, 22414–22420.
- 28 Verri, A., Focher, F., Priori, G., Gosselin, G., Imbach, J. L., Capobianco, M., Garbesi, A. and Spadari, S. (1997) Lack of enantiospecificity of human 2'-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. *Mol. Pharmacol.* **51**, 132–138.
- 29 Spadari, S., Maga, G., Verri, A. and Focher, F. (1998) Molecular basis for the antiviral and anticancer activities of unnatural L-β-nucleosides. *Exp. Opin. Invest. Drugs* **7**, 1285–1300.
- 30 Fridland, A., Connelly, M. C. and Ashmun, R. (1990) Relationship of deoxynucleotide changes to inhibition of DNA synthesis induced by the antiretroviral agent 3'-azido-3''-deoxythymidine and release of its monophosphate by human lymphoid cells (CCRF-CEM). *Mol. Pharmacol.* **37**, 665–670.
- 31 Yao, S. Y., Ng, A. M., Sundaram, M., Cass, C. E., Baldwin, S. A. and Young, J. D. (2001) Transport of antiviral 3'-deoxy-nucleoside drugs by recombinant human and rat equilibrative, nitrobenzylthioinosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins produced in *Xenopus* oocytes. *Mol. Membr. Biol.* **18**, 161–167.
- 32 Loslao, M. P., Mala, J. F., Larrayoz, I. M., Inzillo, S. M., Casado, F. J. and Pastor-Anglada, M. (2000) Electrogenic uptake of nucleosides and nucleoside-derived drugs by the human nucleoside transporter 1 (hCNT1) expressed in *Xenopus* laevis oocytes. *FEBS Lett.* **481**, 137–140.
- 33 Tammur, J., Prades, C., Arnould, I., Rzhetsky, A., Hutchinson, A., Adachi, M., Schuetz, J. D., Swoboda, K. J., Placek, L. J., Rosier, M. et al. (2001) Two new genes from the human ATP-binding cassette transporter superfamily, ABCC11 and ABCC12, tandemly duplicated on chromosome 16q12. *Gene* **273**, 89–96.
- 34 Yabuuchi, H., Shimizu, H., Takayanagi, S. and Ishikawa, T. (2001) Multiple splicing variants of two new human ATP-binding cassette transporters, ABCC11 and ABCC12. *Biochem. Biophys. Res. Commun.* **288**, 933–939.
- 35 Srinivas, R. V., Connely, M. and Fridland, A. (1997) (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) inhibits HIV-1 replication in epithelial cells, but not T-lymphocytes. *Antiviral Res.* **35**, 23–27.
- 36 Cass, C. E., Young, J. D., Baldwin, S. A., Cabrera, M. A., Graham, K. A., Griffiths, M., Jennings, L. L., Mackey, J. R., Ng, A. M., Ritzel, M. W. et al. (1999) Nucleoside transporters of mammalian cells. *Pharm. Biotechnol.* **12**, 313–352.
- 37 Bradley, G., Juranka, P. F. and Ling, V. (1998) Mechanism of multidrug resistance. *Biochem. Biophys. Acta* **948**, 87–128.
- 38 Gottesman, M. M., Fojo, T. and Bates, S. E. (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. *Nat. Rev. Cancer* **2**, 48–58.
- 39 Gollapudi, S. and Gupta, S. (1990) Human immunodeficiency virus 1-induced expression of P-glycoprotein. *Biochem. Biophys. Res. Commun.* **171**, 1002–1007.
- 40 Yusa, K., Oh Hara, T., Yamazaki, A., Tsukara, S., Satoh, W. and Tsuruo, T. (1990) Cross-resistance to anti-HIV nucleoside analogues in multidrug-resistance human cells. *Biochem. Biophys. Res. Commun.* **169**, 986–990.
- 41 Antonelli, G., Turriziani, O., Cianfriglia, M., Riva, E., Dong, G., Fattorossi, A. and Dianzani, F. (1992) Resistance of HIV-1 to AZT might also involve the cellular expression of multidrug resistance P-glycoprotein. *AIDS Res. Hum. Retroviruses* **8**, 1839–1844.
- 42 Litman, T., Brangi, M., Hudson, E., Fetsch, P., Abati, A., Ross, D. D., Miyake, K., Reseau, J. H. and Bates, S. E. (2000) The multidrug-resistant phenotype associated with overexpression of the new ABC half-transporter, MXR(ABCG2). *J. Cell Sci.* **113**, 2011–2021.

Received 28 March 2002/26 June 2002; accepted 19 July 2002

Published as BJ Immediate Publication 19 July 2002, DOI 10.1042/BJ20020494